Daniel Spratt, MD
Enriched profileChair, Department of Radiation Oncology, and Vincent K. Smith Professor, University Hospitals Seidman Cancer Center / Case Western Reserve University School of Medicine · University Hospitals Seidman Cancer Center
Daniel Spratt is Chair, Department of Radiation Oncology, and Vincent K. Smith Professor, University Hospitals Seidman Cancer Center / Case Western Reserve University School of Medicine at University Hospitals Seidman Cancer Center. OpenAlex indexes 976 publications with 25,665 citations (h-index 76); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Radiation Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Daniel Spratt, MD, is Chair, Department of Radiation Oncology, and Vincent K. Smith Professor, University Hospitals Seidman Cancer Center / Case Western Reserve University School of Medicine. The public record shows 976 publications with 25,665 citations (h-index 76), centered on Prostate Cancer, Kidney Cancer / RCC. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 20 companies, 2 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Prostate cancer and prostatic diseases
- Top research focus: Prostate Cancer
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 64 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uhhospitals.org ↗
- Chair
NCCN Prostate Cancer Guidelines Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uhhospitals.org ↗ - Chair
NRG Oncology Intact Prostate Cancer Subcommittee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Member
National Cancer Institute Genitourinary Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Sponsor: Angela Y. Jia, MD PhD
- MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Sponsor: Case Comprehensive Cancer Center
- Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Industry payments
Updated 14 Oct 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
100%alpha-Adrenergic Blocker100%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
Case Western Reserve University
FY2026$1,218,418UG1CA233234 - Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
Case Western Reserve University
FY2026$528,809U01CA257638 - Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
Case Western Reserve University
FY2025$1,412,352UG1CA233234
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.
Prostate cancer and prostatic diseases
Article2026 - Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy.
Future oncology (London, England)
Article2026 - Trends in Long-Term Survival Among Patients With De Novo Metastatic Cancer.
JCO oncology practice
Article2026 - Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.
Prostate cancer and prostatic diseases
Article2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/daniel-spratt-md-bbae0733
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Daniel-Eidelberg-Spratt-2146882382
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
amportal.astro.org/daniel-spratt-md-35232854
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗ - Other
case.edu/cancer/about-us/news/university-hospitals-seidman-cancer-center-welcomes-new-chair-radiation-oncology-daniel-e-spratt-md-effective-may-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Other
guoncologynow.com/post/daniel-spratt-md-offering-mentorship-purpose-for-aspiring-radiation-oncologists
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →guoncologynow.com ↗ - Other
onclive.com/view/advances-in-adt-personalization-and-molecular-imaging-shape-updated-nccn-prostate-cancer-recommendations-with-daniel-spratt-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Other
uhhospitals.org/for-clinicians/articles-and-news/articles/2022/09/from-mma-fighter-to-radiation-oncologist-combating-prostate-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗ - Other
urotoday.com/video-lectures/lugpa-2024/video/3703-the-current-state-of-radiation-oncology-daniel-spratt.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗ - Spotify
creators.spotify.com/pod/profile/nrg-oncology/episodes/Prostate-Cancer-Analysis-and-Translational-Science-from-ASCO-2026-e3jvr0f
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →creators.spotify.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Vanderbilt University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗ - Board Certified
Radiation Oncology, American Board of Radiology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
Editorial & leadership roles
journal and society appointments- Senior Associate Editor
International Journal of Radiation Oncology, Biology, Physics (IJROBP / "Red Journal")
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uhhospitals.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uhhospitals.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uhhospitals.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Department of Radiation Oncology, Case Western Reserve University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Member
Developmental Therapeutics Program, Case Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Afshin Dowlati, MD
University Hospitals Seidman Cancer Center
Theodoros Teknos, MD
University Hospitals Seidman Cancer Center
Joseph Bokar, MD
University Hospitals Seidman Cancer Center
Brett Glotzbecker, MD
University Hospitals Seidman Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)